T-Therapeutics Raises $91 Million Series A to Advance First-in-Class TCR-CD3 Bispecifics for Cancer and Autoimmune Disease
核心洞察
T-Therapeutics (搜索) successfully expanded its Series A financing by $32 million, bringing the total to $91 million with new investors Tencent (搜索) and BGF (搜索) joining existing shareholders.
The funding will advance the company's pipeline of first-in-class TCR-CD3 bispecifics (搜索) targeting both oncology and autoimmune diseases toward clinical trials.
The company's OpTiMus® platform generates high-specificity human TCRs that can access previously undruggable intracellular targets across multiple disease indications.
Cambridge-based biotechnology company T-Therapeutics (搜索) announced the successful expansion of its Series A financing, raising an additional $32 million to bring the total Series A funding to $91 million. The extension attracted new investors Tencent (搜索) and BGF (搜索), who joined all existing major shareholders including Sofinnova Partners (搜索), F-Prime (搜索), Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures (搜索), and the University of Cambridge Venture Fund.
The additional capital will drive T-Therapeutics (搜索)' pipeline of first-in-class TCR-CD3 bispecifics (搜索) across oncology and autoimmune diseases toward clinical development. The funding will also support exploration of new therapeutic strategies, including T cell subset depletion approaches.
Novel Platform Technology Targets Previously Undruggable Proteins
T-Therapeutics (搜索) leverages its proprietary OpTiMus® TCR (搜索) platform, which can generate an almost unlimited repertoire of high specificity, fully human T cell receptors. This technology enables access to validated but previously undruggable intracellular targets that have been historically challenging to address with conventional therapeutic approaches.
The company combines OpTiMus-derived TCRs with proprietary next-generation CD3 (搜索) T cell engagers (TCEs) that have been engineered for high potency, superior safety, and favorable pharmacokinetics. This combination forms the basis for T-Therapeutics (搜索)' first-in-class bispecific drug candidates.
Pipeline Addresses Pan-Indication Disease Drivers
T-Therapeutics (搜索)' lead oncology asset exploits a pan-tumor driver target that is applicable across multiple different solid tumor (搜索) types. The company's lead immunology program represents a pan-autoimmune bispecific designed for precision immune reset, achieved through the selective depletion of pathogenic immune cells.
"Our transformative medicines tackle upstream disease-drivers that can have pan-indication impact," said Theodora Harold, Chief Executive Officer of T-Therapeutics (搜索). "We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date."
Strategic Focus on Broad Therapeutic Applications
The company's pipeline focuses on upstream disease-drivers with pan-indication potential to deliver significant clinical benefit for patients across both cancer (搜索) and autoimmune disease (搜索) areas. This approach represents a departure from traditional single-indication drug development strategies.
Graziano Seghezzi, Managing Partner at Sofinnova Partners (搜索), highlighted the strategic expansion potential: "This additional capital enables us to expand into T cell subset depletion, one of the most exciting areas in immunology, while continuing to advance oncology programmes. We are now ideally positioned to address both cancer (搜索) and autoimmune disease (搜索), two broad disease areas with critical unmet medical needs."
Investor Confidence in Platform Potential
Luke Rajah, Partner at BGF (搜索), emphasized the leadership team's track record and the platform's unique positioning: "This is a leadership team with an outstanding track record of building successful drug discovery businesses and translating science into medicines. Backed by a syndicate of world-class life sciences investors, T-Therapeutics (搜索) is uniquely positioned to unlock previously undruggable targets with its first-in-class bispecifics."
The successful Series A extension reflects growing investor confidence in T-Therapeutics (搜索)' approach to addressing challenging therapeutic targets through its integrated TCR (搜索)-bispecific platform, positioning the company to advance multiple programs toward clinical development across diverse disease areas.